November 30, 2016 - By Ellis Scott
Rupert Vessey, an insider and also See remarks of the large company Celgene Corp made trade. He sold 2,500 shares of the corporation with the insider sale transaction worth near $307,950 U.S. Dollars – which is calculated based on a stock price of $123.2 per each share. At present, Rupert Vessey owns 1,285 shares which are equivalent to around 0.0002% of the company’s total market cap.
Out of 22 analysts covering Celgene Corporation (NASDAQ:CELG), 18 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 82% are positive. $190 is the highest target while $83 is the lowest. The $137.11 average target is 15.69% above today’s ($118.51) stock price. Celgene Corporation has been the topic of 39 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, September 9 by Jefferies. UBS maintained the shares of CELG in a report on Friday, July 24 with “Buy” rating. The firm has “Buy” rating by Citigroup given on Thursday, February 25. Standpoint Research initiated the stock with “Buy” rating in Thursday, January 14 report. The rating was maintained by Canaccord Genuity with “Buy” on Friday, November 6. The firm has “Buy” rating given on Friday, July 15 by Stifel Nicolaus. The stock has “Buy” rating given by Mizuho on Tuesday, November 8. The firm has “Buy” rating by Suntrust Robinson given on Friday, April 29. JP Morgan upgraded it to “Overweight” rating and $152 target price in Thursday, October 1 report. On Wednesday, October 5 the stock rating was maintained by Jefferies with “Buy”.
Insitutional Activity: The institutional sentiment increased to 1.11 in Q2 2016. Its up 0.12, from 0.99 in 2016Q1. The ratio improved, as 70 funds sold all Celgene Corporation shares owned while 411 reduced positions. 60 funds bought stakes while 418 increased positions. They now own 587.22 million shares or 5.24% less from 619.66 million shares in 2016Q1.
Marshall Wace Ltd Liability Partnership last reported 0.06% of its portfolio in the stock. Segment Wealth Limited Liability Com last reported 2,500 shares in the company. Hilltop Holdings reported 5,896 shares or 0.19% of all its holdings. Bb&T Corporation holds 22,440 shares or 0.05% of its portfolio. Blackrock Japan Limited holds 0.38% or 1.08 million shares in its portfolio. Qs Llc has 0.09% invested in the company for 103,196 shares. Allianz Asset Ag has 2.10M shares for 0.11% of their US portfolio. Thrivent For Lutherans has invested 0.51% of its portfolio in Celgene Corporation (NASDAQ:CELG). The New York-based Jane Street Group Ltd Com has invested 0.03% in Celgene Corporation (NASDAQ:CELG). Pggm holds 373,679 shares or 0.19% of its portfolio. The New York-based Stralem And has invested 1.74% in Celgene Corporation (NASDAQ:CELG). Veritable Limited Partnership last reported 0.15% of its portfolio in the stock. Meiji Yasuda Asset Mgmt Ltd, a Japan-based fund reported 42,382 shares. Airain Ltd has 0.98% invested in the company for 171,482 shares. Atlanta Group Inc has invested 0.59% of its portfolio in Celgene Corporation (NASDAQ:CELG).
Insider Transactions: Since July 28, 2016, the stock had 0 insider buys, and 10 sales for $46.59 million net activity. Friedman Michael A had sold 18,600 shares worth $2.16M. HUGIN ROBERT J sold $11.00M worth of stock or 100,000 shares. Another trade for 15,000 shares valued at $1.64M was made by MARIO ERNEST on Friday, September 23. Shares for $4.92M were sold by CASEY MICHAEL D on Monday, August 22. KAPLAN GILLA sold $1.03M worth of stock or 9,710 shares. PEHL MICHAEL F. also sold $2.67 million worth of Celgene Corporation (NASDAQ:CELG) shares. LOUGHLIN JAMES J had sold 27,500 shares worth $3.14 million on Tuesday, August 23.
The stock decreased 2.96% or $3.62 during the last trading session, hitting $118.51. About 5.47M shares traded hands. Celgene Corporation (NASDAQ:CELG) has risen 15.05% since April 27, 2016 and is uptrending. It has outperformed by 9.83% the S&P500.
Celgene Corporation is a biopharmaceutical company. The company has a market cap of $93.27 billion. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 44.91 P/E ratio. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin).
According to Zacks Investment Research, “Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.”
Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 26. They expect $1.42 earnings per share, up 42.00% or $0.42 from last year’s $1 per share. CELG’s profit will be $1.12B for 20.86 P/E if the $1.42 EPS becomes a reality. After $1.39 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 2.16% EPS growth.
More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Fool.com which released: “Better Buy: Celgene Corporation vs. Merck & Co.” on November 25, 2016, also Fool.com with their article: “Better Buy: Biogen Inc. vs. Celgene Corporation” published on November 15, 2016, Fool.com published: “3 Compelling Reasons to Buy Celgene Corporation Stock Right Now” on November 17, 2016. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Businesswire.com and their article: “Celgene Corporation to Webcast an Analyst and Investor Event from the American ..” published on November 21, 2016 as well as Fool.com‘s news article titled: “Better Buy: Celgene Corporation vs. Bristol-Myers Squibb” with publication date: November 18, 2016.
Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Firm together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott